International Transfer Pricing in the Ethical Pharmaceutical Industry

This report was originally a study commissioned by a number of leading pharmaceutical companies into transfer pricing of ethical pharmaceutical products - that is, those products whose safety & efficacy have been demonstrated by accepted scientific methods. The implications of the study, however, go far beyond this one industry, & can be applied in many different contexts, not least those industries labouring under heavy research & development budgets, governmental regulations or endemic disputes concerning transfer pricing. This detailed & authoritative report will be of particular interest to those involved in high-tech & research-based industries. Subjects covered include: * The nature of the pharmaceutical industry, & the perception of the industry in a number of different quarters, including investors & the general public * Different means of establishing a price are dealt with in detail, including an assessment of the various factors affecting the final selling price of research-based pharmaceutical products * The implications of the movement of active ingredients & finished products in an international operation * The central importance of R&D to the industry is emphasized through close analysis of cost-to-turnover statistics * The factors which lead to governmental interest in transfer prices & an assessment of international guidelines on arm's length prices The text is fully supported by examples & statistics from throughout the pharmaceutical industry, although background information ensures that it is completely accessible to those not familiar with the industry. The report is compiled & written by Maurice H. Collins, former chairman of the working group which produced the 1979 OECD Transfer Pricing Report.Collins, Maurice H. is the author of 'International Transfer Pricing in the Ethical Pharmaceutical Industry', published 2000 under ISBN 9789070125653 and ISBN 907012565X.